You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SPECC1L-RET

Showing 1 - 25 of 237
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)

Active, not recruiting
  • Advanced Nonhaematologic Malignancies
  • Philadelphia, Pennsylvania
  • +20 more
Sep 23, 2022

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +37 more
  • Birmingham, Alabama
  • +171 more
Aug 24, 2022

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

    Recruiting
    • Nonsmall Cell Lung Cancer
    • HS-10365 capsules
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 22, 2023

    RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

    Not yet recruiting
    • RET-altered Non Small Cell Lung Cancer
    • +3 more
    • Chang chun, Jilin, China
      Jinlin Province Cancer Hosipital
    Dec 21, 2022

    Breast Cancer Trial in Singapore (Lenvatinib + Letrozole, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Singapore, Singapore
      Nationa University Hospital
    Jan 4, 2022

    NSCLC Trial in Shanghai (SY-5007)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Sep 4, 2023

    Advanced Solid Tumor Trial in Los Angeles (EP0031)

    Recruiting
    • Advanced Solid Tumor
    • Los Angeles, California
    • +3 more
    Dec 1, 2022

    Refractory Solid Tumors Trial in Seoul (sunitinib)

    Completed
    • Refractory Solid Tumors
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Jun 13, 2022

    Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

    Active, not recruiting
    Has Results
    • Solid Tumor
    • Medullary Thyroid Cancer
    • Guangzhou, Guangdong, China
    • +12 more
    May 9, 2022

    Solid Tumor, Adult, Anemia Deficiency Trial in Saint Herblain (Haemoglobin measure)

    Completed
    • Solid Tumor, Adult
    • Anemia Deficiency
    • Haemoglobin measure
    • Saint Herblain, France
      Institut de Cancérologie de l'Ouest
    Apr 19, 2021

    MDD Trial in Ames (Resistance Exercise Training)

    Active, not recruiting
    • Major Depressive Disorder
    • Resistance Exercise Training
    • Ames, Iowa
      Iowa State University
    Jan 12, 2023

    NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Shanghai, Shanghai, China
    • +1 more
    Mar 17, 2022

    Stroke Trial (Power-focused resistance training)

    Not yet recruiting
    • Stroke
    • Power-focused resistance training
    • (no location specified)
    Apr 18, 2023

    NSCLC, Thyroid Tumors Trial (LOXO-260)

    Temporarily not available
    • Carcinoma, Non-Small-Cell Lung
    • Thyroid Neoplasms
    • (no location specified)
    Sep 20, 2022

    NSCLC Trial in London (MPDL3280A, Vemurafenib, Alectinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • London, United Kingdom
      Univeristy College London Hospital
    Feb 22, 2022

    Epilepsy Trial in Worldwide (Ezogabine: USAN Retigabine (International Nonproprietary Name))

    Completed
    Has Results
    • Epilepsy
    • Ezogabine: USAN Retigabine (International Nonproprietary Name)
    • Birmingham, Alabama
    • +50 more
    Jul 14, 2020

    Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)

    Not yet recruiting
    • Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    • Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
    • Singapore, Singapore
      National Cancer Centre Singapore
    Oct 13, 2022

    RET-altered Solid Tumors Trial in Shanghai (APS03118)

    Recruiting
    • RET-altered Solid Tumors
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Dec 8, 2022

    Non Small Cell Lung Cancer Trial in Seoul (Vandetanib)

    Completed
    • Non Small Cell Lung Cancer
    • Seoul, Korea, Republic of
    • +1 more
    Dec 4, 2020

    Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

    Not yet recruiting
    • Thyroid Cancer
    • +5 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Dec 20, 2022

    NSCLC Trial in Guangzhou (HA121-28 tablet)

    Recruiting
    • NSCLC
    • HA121-28 tablet
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Aug 2, 2022

    Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation Trial in Korea, Republic of, United States (TPX-0046)

    Recruiting
    • Non Small Cell Lung Cancer
    • +4 more
    • Irvine, California
    • +15 more
    Mar 9, 2022